Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones. WATER ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

HL187 is a monoclonal antibody that targets TIGIT (T cell immunoreceptors with Ig and ITIM domains {Immunoreceptor ...

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus zimberelimab ...